Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 5Gynecologic 2Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Melanoma 36Uveal Melanoma 8Brain Neoplasms 4Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Merkel Cell 3Carcinoma, Basal Cell 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Immunoblastic Lymphadenopathy 2Gastrointestinal Stromal Tumors 2Waldenstrom Macroglobulinemia 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Sezary Syndrome 1Seminoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Rare Diseases 1

Interventions

pembrolizumab 28Nivolumab 14Ipilimumab 7Cyclophosphamide 7spartalizumab 6atezolizumab 4Interleukin-2 4fludarabine 3durvalumab 3cemiplimab 3avelumab 3aldesleukin 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Immune Checkpoint Inhibitors 3Docetaxel 3obinutuzumab 2epacadostat 2budigalimab 2bempegaldesleukin 2Pemetrexed 2Paclitaxel 2Leucovorin 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2vocimagene amiretrorepvec 1venetoclax 1utomilumab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × CTLA-4 Antigen × Dermatologic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡